First Trust Nasdaq Pharmaceuticals ETF FTXH
Source: Yahoo Finance (opens in a new tab) Observed · 1 day ago Quotes may be delayed
- Expense ratio
- 0.60%
- Net assets
- $36.2M
- Holdings
- 51
- 12-month distribution yield
- 0.68%
- Asset class
- Equity
First Trust Nasdaq Pharmaceuticals ETF (FTXH) is an exchange-traded fund listed on the Nasdaq in the United States, issued by First Trust. Its category is Equity · US (equity). Its last price was US$42.71 on 20 Oct 2026. Its expense ratio is 0.6% a year, from its prospectus dated 1 Aug 2025. It reported net assets of US$36.24 million as of 30 Jun 2026. Its latest holdings report lists 51 holdings as of 30 Jun 2026. Over the last 12 months it paid distributions of US$0.29 a unit, a 12-month distribution yield of 0.68%, paid quarterly.
Fees
- Total annual operating expenses (gross)
- 0.60%
- Net, after fee waivers or reimbursements
- No waiver stated
- Management fee
- 0.60%
- Prospectus date
- 1 Aug 2025
- Filed with the SEC
- 29 Jul 2025
Size and reporting
- Net assets
- $36,243,671
- Total assets
- $36,260,769
- Holdings as of
- 30 Jun 2026
- Report made public
- 21 Aug 2026 (52 days after the month end)
Top holdings
Largest 25 of 51 positions, as of 30 Jun 2026. Weight is the percent of net assets the fund reported.
| # | Holding | Identifier | Weight | Value (USD) | Type | Country | Currency |
|---|---|---|---|---|---|---|---|
| 1 | ELI LILLY & COMPANY ELI LILLY & COMPANY COM | US5324571083 | 7.77% | $2.8M | Equity (common) | United States | USD |
| 2 | ABBVIE INC ABBVIE INC COM | US00287Y1091 | 7.39% | $2.7M | Equity (common) | United States | USD |
| 3 | MERCK & COMPANY INC MERCK & COMPANY INC COM | US58933Y1055 | 7.07% | $2.6M | Equity (common) | United States | USD |
| 4 | JOHNSON & JOHNSON JOHNSON & JOHNSON COM | US4781601046 | 6.96% | $2.5M | Equity (common) | United States | USD |
| 5 | BRISTOL-MYERS SQUIBB COMPANY BRISTOL-MYERS SQUIBB COMPANY COM | US1101221083 | 6.29% | $2.3M | Equity (common) | United States | USD |
| 6 | BIOGEN INC BIOGEN INC COM | US09062X1037 | 3.84% | $1.4M | Equity (common) | United States | USD |
| 7 | VIATRIS INC VIATRIS INC COM | US92556V1061 | 3.62% | $1.3M | Equity (common) | United States | USD |
| 8 | CARDINAL HEALTH INC CARDINAL HEALTH INC COM | US14149Y1082 | 3.53% | $1.3M | Equity (common) | United States | USD |
| 9 | VERTEX PHARMACEUTICALS INC VERTEX PHARMACEUTICALS INC COM | US92532F1003 | 3.41% | $1.2M | Equity (common) | United States | USD |
| 10 | AMGEN INC AMGEN INC COM | US0311621009 | 3.18% | $1.2M | Equity (common) | United States | USD |
| 11 | PFIZER INC PFIZER INC COM | US7170811035 | 2.97% | $1.1M | Equity (common) | United States | USD |
| 12 | GILEAD SCIENCES INC GILEAD SCIENCES INC COM | US3755581036 | 2.89% | $1.0M | Equity (common) | United States | USD |
| 13 | UNITED THERAPEUTICS CORP UNITED THERAPEUTICS CORP COM | US91307C1027 | 2.72% | $987K | Equity (common) | United States | USD |
| 14 | REGENERON PHARMACEUTICALS INC REGENERON PHARMACEUTICALS INC COM | US75886F1075 | 2.72% | $985K | Equity (common) | United States | USD |
| 15 | JAZZ PHARMACEUTICALS PLC JAZZ PHARMACEUTICALS PLC SHS USD | IE00B4Q5ZN47 | 2.49% | $901K | Equity (common) | Ireland | USD |
| 16 | INCYTE CORP INCYTE CORP COM | US45337C1027 | 2.39% | $867K | Equity (common) | United States | USD |
| 17 | ILLUMINA INC ILLUMINA INC COM | US4523271090 | 1.98% | $719K | Equity (common) | United States | USD |
| 18 | ZOETIS INC ZOETIS INC CL A | US98978V1035 | 1.87% | $677K | Equity (common) | United States | USD |
| 19 | EXELIXIS INC EXELIXIS INC COM | US30161Q1040 | 1.72% | $625K | Equity (common) | United States | USD |
| 20 | CHARLES RIVER LABORATORIES INTERNATIONAL INC CHARLES RIVER LABORATORIES INTERNATIONAL INC COM | US1598641074 | 1.49% | $539K | Equity (common) | United States | USD |
| 21 | MEDPACE HOLDINGS INC MEDPACE HOLDINGS INC COM | US58506Q1094 | 1.41% | $512K | Equity (common) | United States | USD |
| 22 | PTC THERAPEUTICS INC PTC THERAPEUTICS INC COM | US69366J2006 | 1.37% | $497K | Equity (common) | United States | USD |
| 23 | NEUROCRINE BIOSCIENCES INC NEUROCRINE BIOSCIENCES INC COM | US64125C1099 | 1.37% | $495K | Equity (common) | United States | USD |
| 24 | ALKERMES PLC ALKERMES PLC SHS | IE00B56GVS15 | 1.35% | $491K | Equity (common) | Ireland | USD |
| 25 | HALOZYME THERAPEUTICS INC HALOZYME THERAPEUTICS INC COM | US40637H1095 | 1.21% | $438K | Equity (common) | United States | USD |
Breakdowns
Sums of reported weights over every position in the report. Totals can differ from 100% because of derivatives, borrowing and cash.
Asset type
| Type | Weight | Bar |
|---|---|---|
| Equity (common) | 99.90% | |
| Short-term investment vehicles (cash funds) | 0.10% |
Country
| Country | Weight | Bar |
|---|---|---|
| United States | 95.59% | |
| Ireland | 3.84% | |
| Bermuda | 0.57% |
Currency exposure
| Currency | Weight | Bar |
|---|---|---|
| US dollar (USD) | 100.00% |
Sector
| Sector | Weight | Bar |
|---|---|---|
| Health Care | 89.62% | |
| Health Technology | 0.64% |
Source: SEC Form N-PORT (opens in a new tab) Holdings as of
Distributions
- Paid in the last 12 months
- $0.2890
- 12-month yield
- 0.68%
- Frequency
- Quarterly
- Latest ex-date
- 24 Sep 2026
12-month yield = distributions per unit with an ex-date in the last 12 months ($0.2890) ÷ latest price ($42.71) × 100 = 0.68%. It looks back, so it is not a forecast; special distributions in the window are included.
Why a distribution yield is not the fund's return: yield vs total return
Distribution history table (20 payments)
| Ex-date | Amount per unit |
|---|---|
| 24 Sep 2026 | $0.0110 |
| 25 Jun 2026 | $0.0920 |
| 26 Mar 2026 | $0.0570 |
| 12 Dec 2025 | $0.1290 |
| 25 Sep 2025 | $0.1450 |
| 26 Jun 2025 | $0.0890 |
| 27 Mar 2025 | $0.0990 |
| 13 Dec 2024 | $0.1300 |
| 26 Sep 2024 | $0.1220 |
| 27 Jun 2024 | $0.1280 |
| 21 Mar 2024 | $0.0680 |
| 22 Dec 2023 | $0.1230 |
| 22 Sep 2023 | $0.0730 |
| 27 Jun 2023 | $0.1180 |
| 24 Mar 2023 | $0.1000 |
| 23 Dec 2022 | $0.1250 |
| 23 Sep 2022 | $0.0910 |
| 24 Jun 2022 | $0.0380 |
| 25 Mar 2022 | $0.0490 |
| 23 Dec 2021 | $0.1100 |
Filings and sources
- Form N-PORT report for June 2026 (opens in a new tab)
- Prospectus filing with the fee table (opens in a new tab)
- All SEC filings for this fund series (S000053945) (opens in a new tab)
- Nasdaq Trader symbol directory (opens in a new tab)
- Yahoo Finance quote and distributions (opens in a new tab)
- How the ETF figures are collected
Compare with
Largest funds in the same category:
- FTXH and VTI Vanguard Morningstar Total Stock Market ETF
- FTXH and VOO Vanguard S&P 500 ETF
- FTXH and IVV iShares Core S&P 500 ETF
- FTXH and QQQ Invesco QQQ Trust, Series 1